Cargando...
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
Drug combination trials are increasingly common nowadays in clinical research. However, very few methods have been developed to consider toxicity attributions in the dose escalation process. We are motivated by a trial in which the clinician is able to identify certain toxicities that can be attribu...
Gardado en:
| Publicado en: | Biom J |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6261712/ https://ncbi.nlm.nih.gov/pubmed/29808507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bimj.201700166 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|